Mechanisms of immune evasion in bladder cancer

Paul L. Crispen1 · Sergei Kusmartsev1

Received: 26 February 2019 / Accepted: 27 November 2019 / Published online: 6 December 2019
© The Author(s) 2019

Abstract
With the introduction of multiple new agents, the role of immunotherapy is rapidly expanding across all malignancies. Bladder cancer is known to be immunogenic and is responsive to immunotherapy including intravesical BCG and immune checkpoint inhibitors. Multiple trials have addressed the role of checkpoint inhibitors in advanced bladder cancer, including atezolizumab, avelumab, durvalumab, nivolumab and pembrolizumab (all targeting the PD1/PD-L1 pathway). While these trials have demonstrated promising results and improvements over existing therapies, less than half of patients with advanced disease demonstrate clinical benefit from checkpoint inhibitor therapy. Recent breakthroughs in cancer biology and immunology have led to an improved understanding of the influence of the tumor microenvironment on the host’s immune system. It appears that tumors promote the formation of highly immunosuppressive microenvironments preventing generation of effective anti-tumor immune response through multiple mechanisms. Therefore, reconditioning of the tumor microenvironment and restoration of the competent immune response is essential for achieving optimal efficacy of cancer immunotherapy. In this review, we aim to discuss the major mechanisms of immune evasion in bladder cancer and highlight novel pathways and molecular targets that may help to attenuate tumor-induced immune tolerance, overcome resistance to immunotherapy and improve clinical outcomes.

Keywords Bladder cancer · Cancer immunotherapy · Immune tolerance · Immune evasion · Tumor microenvironment

Introduction
Bladder cancer is the ninth most common malignancy worldwide and the fifth most common in developed countries. Approximately 20% of patients are diagnosed with muscle-invasive disease at the time of initial presentation, which will require multiple treatment modalities due to the high rates of disease recurrence, progression and disease-specific mortality. Treatment options include chemotherapy, radiation therapy, and radical cystectomy in cases of clinically localized disease and systemic chemotherapy for patients with metastatic disease. Despite this aggressive treatment approach
prognosis remains poor for many patients. The continued poor prognosis observed presents an opportunity for immunotherapy to improve outcomes. During the past two decades, several revolutionary immunotherapy approaches have taken center stage in cancer therapy. These approaches include checkpoint inhibitors PD-L1/PD1, CTLA-4 as well as CAR T cell therapy [1–3]. Anti-PD-L1/PD1 and anti-CTLA-4 therapies that are based on antibody treatment have shown significant clinical effects in various solid cancers, including bladder cancer. However, there is still an unmet need, as the majority of patients do not respond to the immunotherapy in all stages of bladder cancer. A greater understanding of the mechanisms of resistance to immunotherapy may provide alternate strategies to improve bladder cancer care. In this review, we discuss the current use and limitations of immunotherapy in bladder cancer and explore various mechanisms of resistance to immunotherapy, which may serve as future therapeutic targets.

**Immunotherapy for bladder cancer**

**Bacillus-Calmette–Guerin**

Intravesical Bacillus-Calmette–Guerin (BCG) was first approved for use in the United States in 1990 for stage I bladder cancer. Currently, it is the most common form of immunotherapy used for bladder cancer. BCG induces an initial complete response rates of 55–70% in patients with high-risk stage I bladder cancer. Conversely, despite high initial success rates, as many as 25–45% of patients will not respond, and an additional 40% of patients will eventually relapse despite showing initial success [4]. While the exact mechanism of action remains unknown, BCG is known to induce a robust innate immune response leading to long-lasting adaptive immunity [5]. The inciting events leading to this immune response may involve multiple pathways including BCG attachment to and internalization within the urothelium. The process of BCG attachment to the urothelium has been widely studied with inconsistent results on its importance to the efficacy of treatment. Similarly, BCG internalization into the urothelium may be possible but is likely only transient with decreasing mycobacterial DNA being detected in the urine overtime following instillation. Regardless of the manner of induction, BCG stimulates an innate immune response locally and systemically. Following initial instillation cytokine and chemokine concentrations peak within 2–8 h leading to immune cell recruitment to the urothelium. The roles of neutrophils, natural killer (NK) cells, CD8+ T cells, and macrophages have all been explored individually with all of these cells appearing to be important in the initial response. This innate response is further characterized by granuloma formation in the bladder wall, containing macrophages, dendritic cells (DCs), lymphocytes, neutrophils and fibroblasts [6, 7]. Induction of adaptive immunity also appears critical for the success of BCG therapy. The importance of T cells in the response to BCG has been clearly demonstrated in both animal and human studies [5–7]. Furthermore, the importance of adaptive immunity is supported with improved 5-year disease-free survival of 80% patients with a positive PPD test prior to the initiation of BCG therapy compared to only 45% in patients who were PPD negative prior to the initiation of BCG therapy [8]. Enhancing the immune response to BCG may further improve patient outcomes. While the initial trial evaluating BCG vaccination with intravesical therapy did not show clinical benefit, ongoing clinical trials may provide greater insight into the importance of the adaptive immune response due to the timing and manner of BCG vaccination. [9, 10].

**Immune checkpoint blockade**

Immune checkpoint blockade (ICB), including anti-PD1/ PD-L1 and anti-CTLA-4 therapies has shown tremendous success in the treatment of human cancers, particularly for solid tumors. Cancers with high mutational burden including Hodgkin’s lymphoma, melanoma, renal cell carcinoma, non-small lung cancer carcinoma, urothelial bladder carcinoma have all demonstrated promising response rates to anti-PD1/ PD-L1 antibody therapies [11–16].

Multiple studies have demonstrated that blocking PD-1 or its ligand, PD-L1, result in encouraging rates of anti-tumor activity in patients with metastatic urothelial cancer who had disease progression following standard chemotherapy. Currently, the United States Food and Drug Administration has approved two PD1 inhibitors (Nivolumab and Pembrolizumab) and three PD-L1 inhibitors (Atezolizumab, Avelumab, and Durvalumab) for the treatment of advanced urothelial carcinoma. The overall response rates noted in clinical trials leading to approval ranged from 15 to 29% across the approved agents. Importantly, trials that randomized patients to PD1/PD-L1 inhibition versus investigator choice of single-agent chemotherapy demonstrated remarkable improvements in side effect profile and survival. IMvigor 211, sponsored by Hoffman-La Roche, was a randomized phase III trial comparing Atezolizumab versus investigator choice single-agent chemotherapy in patients with disease progression/recurrence after platinum-based chemotherapy [17]. While no advantage was noted with Atezolizumab in overall response rate, 23% versus 21%, and overall survival, 11.1 months versus 10.6 months, the side effect profile was significantly more favorable in patients receiving Atezolizumab [18]. Treatment-related adverse effects, 69.5% versus 89.2%, and treatment-related grade 3–4 adverse
effects were significantly lower in patients receiving Atezolizumab compared to single-agent chemotherapy. Keynote-045, sponsored by Merck, randomized patients with disease progression/recurrence following platinum-based chemotherapy to Pembrolizumab versus investigator choice single agent choice chemotherapy. Patients receiving Pembrolizumab demonstrated a significant increase in overall response rate, 21% versus 11%, and median overall survival, 10.3 months versus 7.4 months. Additionally, the number of adverse events and the severity of adverse events were lower in patients receiving Pembrolizumab. While these trials suggest that PD1/PD-L1 inhibitors have favorable side effect profiles compared to chemotherapy, side effect profiles vary between individual PD1/PD-L1 inhibitors. Factors believed to influence the variation in side effect profile between individual PD1/PD-L1 inhibitors include the primary site of cancer being treated and selectivity of the antibodies [19]. With the favorable results from multiple trials, the National Comprehensive Cancer Network guidelines now recommend Pembrolizumab as a preferred regimen in patients with disease progression/recurrence of locally advanced or metastatic urothelial carcinoma following platinum-based chemotherapy. Alternative preferred regimens for this patient population include Atezolizumab, Nivolumab, Durvalumab, and Avelumab [20, 21]. For patients that are not eligible for cisplatin as first-line therapy, Atezolizumab and Pembrolizumab are preferred first-line regimens. Although the initial results of trials evaluating PD1/PD-L1 inhibition in advanced urothelial carcinoma are promising, a large majority of patients do not respond to anti-PD-L1 antibody monotherapy. Investigations exploring the potential value of biomarkers predicting treatment response are ongoing. To date, multiple biomarkers have been evaluated to predict response to PD1/PD-L1 inhibition in urothelial carcinoma. PD1 expression within the tumor has been associated with an increased overall response rate in multiple trials, however, patients with tumors without PD1 expression have also demonstrated response limiting this biomarker for treatment selection. Higher tumor mutation burden, interferon-gamma gene expression, and DNA damage repair alterations have also been associated with response rates but require additional validation.

However, not all tumors express PD-L1 and display immune infiltration (“cold tumor microenvironment”). In this case, combination of conventional therapy, including chemotherapy, radiation and immune checkpoint inhibitors may improve the response rates, as tumor cell death initiated by radiation or chemotherapy may release tumor-antigens, attract antigen-presenting cells and stimulate a T cell-mediated anti-tumor immune response. The resulting immune response may be further enhanced by applying checkpoint inhibitors [22].

Mechanisms of immune evasion in bladder cancer

Bladder cancer represents an ideal disease state to study immune evasion and mechanisms by which to improve the immune response based on several established features. These features include distinct molecular/genomic subtypes of bladder cancer, known response rates to currently available immune therapy, and unique opportunity to study treatment response. Altered signaling pathways and protein expression in bladder cancer include, but are not limited to the p53/cell cycle, DNA repair, PI3K/AKT, and chromatin modifications. Molecular subtypes can be categorized based on these alterations which show differing response rates to chemotherapy clinically, but also demonstrate associations within the tumor microenvironment including the degree of inflammation and distribution of tumor-infiltrating lymphocytes [23]. The amount of inflammation and tumor-infiltrating lymphocytes has been associated with overall survival, presenting a potential opportunity for initiating the immune response in tumors with low levels of inflammation. Additionally, The Cancer Genome Atlas (TCGA) study found that genes regulating chromatin remodeling are more frequently mutated in bladder cancer than in other type of cancer, which may represent an additional target for novel therapies to be given in combination with immunotherapy [24]. Furthermore, bladder cancer is associated with one of the highest mutation burdens among all types of cancer which is a known predictor of treatment response to checkpoint inhibitors [24]. Additionally, neoantigens produced from cancer somatic mutations are positively associated with response to anti-PD-1 or anti-CTLA-4 treatment [25]. These mutations may also add more complexity to the tumor microenvironment, regulating expression of inhibitory or stimulatory molecules. Lastly, bladder cancer provides a unique opportunity to study treatment response due to the ability to access the bladder for repeat resections of primary tumors and administration of intravesical therapy. These features can allow for a minimally invasive manner to assess treatment response and evaluate new therapies while potentially decreasing systemic toxicity by limiting exposure of the treatment to the bladder surface.

Immunosuppressive tumor microenvironment

Despite the success of immunotherapy in the treatment of bladder cancer, there remains a tremendous opportunity to improve response rates and prediction of treatment response. Mechanisms of immune evasion in bladder cancer beyond PD1/PD-L1 expression may offer additional
therapeutic targets to improve patient outcomes. Tumors evade immune surveillance through multiple mechanisms. The ability to escape the immune system is an important characteristic of malignant cells, which enhances tumor survival, proliferation and dissemination. Therefore, identifying specific mechanisms of immune evasion could improve the efficacy of existing cancer immunotherapies by removal tumor-induced immunosuppression and boosting the host’s immune response against tumors.

One of the hallmarks of cancer progression is a formation of immunosuppressive and tolerogenic tumor microenvironment [26]. Tumor tissue itself is highly heterogeneous, dynamic and consists of epithelial tumor cells, immune infiltrating cells, vascular cells, stromal cells and an extracellular matrix (ECM). To develop an effective anti-tumor immune response that will result in immune-mediated tumor eradication, a concerted effort of antigen-presenting cells (APCs) (DCs, macrophages), lymphocytes (CD8, CD4) and NK cells is required. To survive and escape the normal response of these immune cells, tumors secrete various immunosuppressive and anti-apoptotic factors including TGF-beta, PGE2, IL-10, and IL-6 [26–29], creating a highly tolerogenic microenvironment. In addition, the tumor microenvironment is tightly linked to the accumulation of several types of immune cells with immunosuppressive phenotypes such as myeloid-derived suppressor cells (MDSCs), tolerogenic DCs (tDCs), tumor-associated macrophages (TAMs) and regulatory T cells (Tregs). These changes have all been noted in bladder cancer (Figs. 1, 2), which is characterized by a highly immunosuppressive microenvironment that includes increased expression of the inhibitory ligand PD-L1, the strong presence of MDSCs, TAMs, increased PGE2 production and aberrant metabolism of glycosaminoglycans such as hyaluronic acid or hyaluronan.

**PD-L1/PD1 pathway**

The immunosuppressive ligand PD-L1 can be expressed by tumor cells and by the host’s myeloid cells. Since PD-L1-expressing cells can induce apoptosis or anergy of activated T lymphocytes through binding of PD-L1 to cognate receptor PD1 (CD279) on T cells, PD-L1-mediated inhibition of activated PD1+ T lymphocytes is considered a major mechanism for tumor immune escape [30]. Blockade of PD-L1/PD1 signaling attenuates tumor-induced immune suppression and successfully inhibits tumor growth due to preservation of a T cell mediated anti-tumor immune response. Recent studies demonstrated that PD-L1 expression on host APCs, such as macrophages and DCs, is essential for PD-L1 mediated immune evasion [31, 32]. We recently reported that bone marrow-derived myeloid progenitors, including MDSCs, differentiate into highly immunosuppressive PD-L1+ macrophages upon contact with tumor cells [33].

Interestingly, many human or murine tumor cell lines do not express PD-L1 constitutively, but at the same time, most of surgically removed tumors demonstrate high expression of PD-L1 [30, 33]. This finding may suggest that inflammatory
or immune cells recruited to the malignant tissues, could be involved in the mechanisms of PD-L1 expression induction within the tumors. Additionally, cytokines and other immunosuppressive factors secreted by tumor-recruited myeloid cells play multifaceted roles in mechanisms of regulation of PD-L1 expression.

**Myeloid-derived suppressor cells**

Accumulation of MDSCs in the tumor microenvironment has been extensively reported in various experimental models and in human tumors. MDSCs are a heterogeneous population of immature myeloid cells that are recruited to the primary tumor as well as metastatic sites and play a crucial role in inhibiting innate and adaptive immune responses by suppressing CD4 T-cells, CD8 T-cells, and NK cells [34]. In the clinical setting, an increased number of MDSCs correlates with weakened clinical responses to immunotherapy. Moreover, low levels of circulating or tumor-infiltrating MDSCs have been attributed to an improved prognostic and predictive value in a variety of oncologic settings [35]. Multiple studies have shown that CD11b-expressing MDSCs play a profound role in suppressing the antigen-specific T cell response. Morphological analyses have shown that MDSCs are comprised of myeloid cells and their precursors at various stages of differentiation. The two major myeloid cell subsets of MDSCs, monocytic and granulocyte-type cells, are detected in peripheral blood of cancer patients [34, 36]. In the presence of specific growth factors and/or cytokines, monocytic MDSCs can differentiate into mature DCs or macrophages in vitro as well as in vivo. However, tumor-derived products prevent this developmental pathway favoring formation and accumulation of immunosuppressive MDSCs [34].

Patients with bladder cancer have an increased amount of MDSCs in peripheral blood compared to healthy donors [37, 38]. These MDSCs are represented by both cell subsets: granulocytic CD15^{high} CD33^{low} HLA-DR^{neg} and monocytic CD15^{low} CD33^{high} HLA-DR^{neg} MDSCs. Cytokine/chemokine profiling of these MDSCs demonstrated that both myeloid cell subsets from cancer patients produced substantial amounts of CCL2, CCL3, CCL4, G-CSF, IL-8 and IL-6. Furthermore, isolated granulocytic MDSCs exhibited immunosuppressive activity by inducing CD4^{+}Foxp3^{+} T regs cells and inhibiting the T cell proliferative response. Furthermore, analysis of tumor tissue obtained from patients with bladder cancer showed significant presence of immature myeloid cells including HLA-DR-negative TAMs and HLA-DR-positive TAMs. Similarly, bladder tumor-infiltrating MDSCs consisted of the two major cell subsets: monocytic and granulocytic [37]. Altogether, these data suggest that human bladder cancer is associated with an increased number of myeloid cells in both the peripheral blood and tumor tissue. Those myeloid cells secrete significant amounts of pro-inflammatory and immunosuppressive cytokines/chemokines which contributes to cancer-related inflammation and immune evasion.

Additional data on the importance of the interaction between the bladder cancer microenvironment and myeloid cells has been demonstrated in vivo. Human bladder cancer cells implanted into immunodeficient mice become quickly infiltrated with the host’s myeloid cells, including MDSCs and macrophages [39]. Fast-growing SW780 tumors are characterized by more active recruitment of myeloid cells into tumor tissues (up to 40% of total tumor cell population). Those SW780 tumor-infiltrating myeloid cells were mostly represented by MHC class II-positive F4/80^{+} macrophages and Ly6C^{+}F4/80^{+} macrophage precursors. Slow-growing Urothel 11 bladder tumors were less capable in the recruitment of myeloid cells into the tumor bed (up to 25% of total tumor cell population). Analysis of intra-tumoral myeloid cells showed that the majority of these cells displayed an immature phenotype including Ly6c^{+}F4/80^{−} MDSCs and Ly6C^{−}F4/80^{−} macrophage precursors. This data suggests that tumor growth rate and tumor size may influence the tumor’s ability: (1) to recruit myeloid cells and (2) convert recruited myeloid cells into tumor-promoting TAMs.

Using an experimental mouse model of bladder cancer, we demonstrated that Gr-1^{+} MDSCs isolated from the spleen of MBT2-tumor bearing mice or naïve bone marrow are able to differentiate into highly immunosuppressive PD-L1^{+} macrophages upon contact with bladder cancer cells [32]. This tumor-mediated PD-L1 expression in myeloid cells was dependent on PGE_2 production, since in vitro and in vivo inhibition of PGE_2 synthesis with pharmacological inhibitors markedly reduced PD-L1 by myeloid cells. PD-L1^{+} cells isolated from tumor tissue also displayed the morphology of TAMs and expressed high levels of PGE_2-forming enzymes mPGE1 and COX2.

**Tumor-associated macrophages**

TAMs are considered one of the major players in the regulation of the immune responses in cancer (Fig. 3) and are abundant in the tumor stroma at all stages of cancer progression. Macrophages are known to contribute to metastasis by priming the pre-metastatic site and enabling tumor cell extravasation and survival [40, 41]. Furthermore, it has been shown that TAMs orchestrate angiogenesis by secreting pro-angiogenic molecules that increase the tumor vascular density and promote a chronic inflammatory environment permissive for tumor initiation and growth through the release of inflammatory cytokines. Additionally, extensive TAM infiltration positively correlates with cancer metastasis and poor clinical prognosis in a variety of human cancers [40, 41].
TAMs can differentiate from circulating blood CD14 monocytes or from tumor-recruited MDS Cs. Phenotype, cytokine profile and immune function of these cells are tightly regulated by the tumor microenvironment. Both clinical studies and experimental mouse models indicate that TAMs are typically polarized by the local tumor milieu to adopt pro-tumoral characteristics and frequently acquire a M2 phenotype in tumor microenvironment. TAMs greatly contribute to the formation of a tolerogenic tumor microenvironment by direct elimination of CD8 T cells [42, 43], supporting induction and trafficking of T regs [44–46] and secreting immunosuppressive cytokines and bioactive lipids [47, 48]. TAMs frequently express PD-L1 and are capable of inhibiting tumor growth via stimulation of tumor angiogenesis, tumor invasion, inflammation and immune escape.

Regulatory T cells

Previously published studies have identified a subset of T cells, which act in a regulatory capacity by suppressing the function of other T cells [57, 58]. The role of T regs is to dampen chronic immune responses against viruses, tumors and self-antigens. T regs develop from circulating CD4 T helper cells in response to antigen-specific presentation by tDCs or by TAMs and are characterized by expression of the transcription factor FOXP3. A common trait of all T regs is the expression of one or more anti-inflammatory molecules, such as IL-10, TGFβ or IL-35 and/or inhibitory receptors such as CTLA-4, LAG-3, GITR among others [59]. Accordingly, elevated levels of T regs in the peripheral blood and accumulation within tumor tissue and lymph nodes have been detected in patients with urothelial carcinomas and other malignancies [60, 61]. In a recently published study, the level of T regs in human bladder tissue significantly correlated with both TAMs and with IL-6-positive cancer cell count [50]. FOXP3+ CD4+ T regs accounted for over 20% of the CD4+ T-cell population. Bladder cancer-infiltrating CD4+FOXP3+ T cells did not produce IL-2 or IFN-γ even upon stimulation, and readily suppressed autologous CD4+ effector T cells, confirming that tumor-infiltrating CD4+FOXP3+ T cells act functionally as T regs. Similar functional findings have been reported for other solid tumors, including melanoma and ovarian cancer.
PGE$_2$ metabolism and immune evasion

Due to the high expression of the inducible inflammatory enzyme COX2, bladder carcinoma tissues secrete substantial amounts of PGE$_2$ [39, 62]. Endogenously released PGE$_2$, the major metabolite of the COX pathway, plays multifaceted roles in cancer progression, cancer-related immune inflammation and immune evasion. This lipid metabolite exhibits strong anti-apoptotic effects, supports proliferation and renewal of bladder cancer stem cells and induces resistance to chemotherapy [63]. In regard to regulation of the immune response, it is reported that PGE$_2$ inhibits antigen-presenting cell differentiation [64–67], stimulates expression of arginase I in myeloid cells and promotes accumulation of MDSCs in a dose-dependent manner [68, 69]. Furthermore, PGE$_2$ promotes recruitment of Tregs to the tumor site and induces Foxp3 in T cells [70, 71]. This lipid metabolite also inhibits the NK-mediated cytotoxic activity against tumors and transactivates the M-CSF1 receptor and synergizes with colony-stimulating factor-1 in the induction of M2 macrophages via the mitogen-activated protein kinase ERK1/2 [72]. PGE$_2$ strongly suppresses IFN-γ and IL-2 production by T cells and NK cells while enhancing IL-4 and IL-10 production, thereby promoting a Th$_2$ over Th$_1$ immune response [73, 74]. Furthermore, inhibition of PGE$_2$ secretion during the induction of Ag-specific immunity results in enhanced immune and therapeutic activity of cancer vaccines [75].

In addition to tumor cells, myeloid cells that infiltrate tumor tissue also demonstrate increased PGE$_2$ production via upregulated expression of COX2 and mPGES1 [33, 76]. Elevated levels of PGE$_2$ in the tumor microenvironment in combination with other tumor-derived factors affect the immune function of APCs by driving their differentiation toward immunosuppressive PD-L1-expressing macrophages [33]. Increased expression of COX2/mPGES1 in myeloid cells was associated with driving the differentiation of macrophages toward the M2 phenotype characterized by increased arginase activity and production of pro-tumoral factors such as IL-10, VEGF and CXCL2. Notably, tumor-infiltrating myeloid cells were also characterized by down-regulated expression of the major PGE$_2$-catabolizing enzyme 15-hydroxyprostaglandin dehydrogenase (15-PGDH) [76]. By inactivating endogenous PGE$_2$, this enzyme provides a natural way of reducing the intracellular levels and regulating extracellular secretion of this lipid metabolite. Remarkably, both pharmacological inhibition of COX-2/mPGES1 pathway and genetic restoration of 15-PGDH expression in myeloid cells could significantly reduce the tumor-mediated inhibitory effects on myeloid cells and improve their immune function [33, 75]. Together, these data indicate that aberrant PGE$_2$ metabolism in tumor microenvironment markedly affects the immune function of tumor-infiltrating cells thus helping tumor cells to evade the immune response and promote tumor growth.

Epigenetic mechanisms seem to be responsible for the tumor-mediated deregulation of PGE$_2$ metabolism in myeloid cells in cancer [77]. Thus, MDSCs isolated from patients with ovarian cancer displayed increased expression of DNA methyltransferase 3A (DNMT3A) levels that caused an extensive gene hypermethylation in PGE$_2$-dependent manner. The hypermethylation signature in myeloid cells resulted in repression of specific genes associated with the immune response and promoted an immunosuppressive phenotype of myeloid cells. Down-regulation of DNMT3A levels markedly reduced MDSC-specific hypermethylation and attenuated their immunosuppressive function. We also previously reported [78] that treatment of tumor-infiltrating myeloid cells with DNA methylation inhibitor 5-aza-2′-deoxycytidine (5-AZA) promoted their differentiation toward mature APCs and markedly improved immune function. Collectively, these studies link PGE$_2$-dependent DNA hypermethylation in cancer with tumor-associated inhibition of APC differentiation and concomitant accumulation of immunosuppressive myeloid cells.

There is a growing body of evidence demonstrating that PGE$_2$ effectively inhibits DC differentiation while promoting macrophage and or MDSCs development, particularly in a combination with IL-6 [79–82]. Combination of PGE$_2$ and IL-6 seems to be crucial for immune evasion in cancer. Thus, IL-6 alone could switch differentiation of DCs toward macrophages [82], and activates the transcription factor STAT3 which is required for up-regulation of PD-L1 expression [55]; while high levels of PGE$_2$ inhibit DC differentiation, promotes accumulation of MDSCs and drives the cytokine profile toward the M$_2$ phenotype in DCs/macrophages and Th$_2$ type in T cells [68]. Altogether, these data indicate that enhanced and deregulated PGE$_2$ metabolism in the bladder cancer promotes the formation of immunosuppressive tumor-supporting microenvironment.

Bladder cancer and tumor-infiltrating inflammatory cells in advanced tumors are positive for COX2 and exhibit increased expression of another PGE$_2$-producing enzyme, mPGES1 [33]. High levels of PGE$_2$ in tumor tissue have a strong impact on the function of infiltrating immune cells including the inhibition of APCs, effector T cell function and stimulation of MDSC generation directly through PGE$_2$-specific EP2 and EP4 receptors. We have previously demonstrated that human bladder tumors secrete substantial amounts of PGE$_2$ [39]. Culture of bone marrow-derived myeloid cells in PGE$_2$-enriched bladder tumor-conditioned medium markedly inhibited the in vitro generation of mature APCs, while promoting the accumulation of monocytic MDSCs and macrophages.
Emerging targets to remodel immunosuppressive microenvironment and improve the effects of bladder cancer immunotherapy

CCR2/CCL2 axis

Chemokines and their receptors are involved in tumor progression by controlling cancer-related inflammation including the recruitment of immune cells to tumor tissue and lymphoid organs [83, 84]. Chemokine receptor 2 (CCR2) is a protein which represents one of the 19 chemokine receptors that are expressed predominantly by leukocytes. CCR2 expression was detected on monocytic myeloid cells including CD14 monocytes and its myeloid precursors, whereas its specific ligand CCL2 (MCP1) is produced by tumor and stromal cells. CCR2-expressing cells migrate to the source of CCL2 and are frequently recruited to tumor tissue, where they differentiate into tumor-promoting TAMs. In addition to the macrophage infiltration, the CCL2-mediated signaling axis has been implicated to the metastatic process in various cancers [85–89]. Targeting the CCR2–CCL2 axis reduced TAM accumulation at the metastatic site, thereby disrupting the immunosuppressive tumor microenvironment and improving the anti-tumor T-cell response. Notably, inhibition of CCL2 alone or in combination with anti-IL-6 therapy markedly reduced metastases and increased survival of the tumor-bearing animals [88].

In bladder cancer, CCL2/CCR2 interaction has been implicated in the stimulation of lymphoangiogenesis and development of lymphatic metastasis via macrophage tumor infiltration and VEGF-c production [90]. Mechanistically, the long noncoding RNA LNMAT1 epigenetically activates CCL2 expression via an activating promoter, which leads to increased histone methylation and enhanced VEGF-c transcription. In bladder cancer, myeloid cells isolated from peripheral blood secreted significant amounts of CCL2 constitutively [38]. Altogether, these findings provide a plausible mechanism for CCL2 in the recruitment of CCR2-expressing myeloid cells subsets to the tumor, thus promoting macrophage tumor infiltration and macrophage-mediated development of lymphatic metastasis. This suggests that the CCR2–CCL2 axis may represent a potential therapeutic target in bladder cancer.

CCR8/CCL1, CCL18 axis

CCR8 belongs to the G protein-coupled receptor (GPCR) family. The natural ligands for CCR8 are CCL1 and CCL18. Expression of CCR8 is noted in several types of immune cells including T regs, monocytes, peritoneal macrophages, Langerhans cells and NK cells, but not in tumor cells [91–93]. Functionally, CCR8 has been implicated in cell migration, aggregation and cytokine production [94, 95] in response to cognate ligands. We previously demonstrated that monocytic and granulocytic myeloid cells obtained from peripheral blood and in tumor-infiltrating leukocytes of patients with bladder cancer display an increased expression of CCR8 [38]. Primary bladder cancers secrete substantial amounts of the natural CCR8 ligand CCL1. Remarkably, CCR8 expression detected in bladder cancer tissue and was limited to the tumor-infiltrating myeloid cells, including TAMs. We also noted that the tumor-infiltrating CD11b+CCR8+ cell subset responsible for the production of the greatest levels of pro-inflammatory (IL-6, CCL3, CCL4) and pro-angiogenic (VEGF) factors among intra-tumoral myeloid cells. Furthermore, CD11b+CCR8+ cells were noted to induce FOXP3 expression in T lymphocytes [37].

Recent studies support a tolerogenic nature of CCR8-expressing cells and its ligand CCL1 [96, 97]. Thus, recombinant CCL1 in a dose-dependent manner is capable of inducing FOXP3 transcription factor in CD4 T cells. Furthermore, administration of anti-CCR8 antibody in mice with transplanted colorectal tumors significantly inhibited tumor growth [97]. The anti-tumor effects were accompanied with reduction of both, T regs and MDSCs. Given the increased levels of CCR8-expressing cells in patients with bladder cancer, CCR8 and/or CCR8-related ligands could represent an attractive target for therapy of bladder cancer.

mPGES1

Increased COX2-dependent PGE2 production strongly contributes to the formation of an immunosuppressive and tumor-promoting microenvironment. Due to adverse effects of COX inhibitors on the cardiovascular system, stomach and kidney [98, 99], novel approaches that target the increased and deregulated PGE2 production warranted. Microsomal PGE synthase 1 (mPGES1) is microsomal prostaglandin E synthase-1 (mPGES-1), the key terminal enzyme involved in the synthesis of PGE2. This is an integral membrane enzyme, which is highly expressed at sites of inflammation, and considered to be responsible for the excessive PGE2 synthesis and is suggested as a promising target for suppressing PGE2 biosynthesis [100, 101]. mPGES-1 gene knockdown in cancer cell lines resulted in decreased clonogenic capacity, slower growth and increased apoptosis of tumor cells, which could be rescued by exogenous PGE2 [102]. Since mPGES1 is critically involved in PGE2 production, it inevitably contributes to PGE2-mediated cancer-related inflammation and formation of immunosuppressive tumor

 Sparcen Springer
microenvironment. Recent studies suggest that inhibition of mPGES1 activity resulted in reduced PD-L1 expression in myeloid cells infiltrating bladder tumor tissue [33]. Furthermore, expression of mPGES1 is necessary for induction of Tregs and IL-17-producing T cells during primary immune response [103]. Altogether, these data indicate that targeting mPGES1 in bladder cancer could reduce the tumor-associated immunosuppression and improve the efficacy of cancer immunotherapy.

**Tumor-produced hyaluronan**

Microenvironmental signals determine the differentiation and distinct function of macrophages. Hyaluronan or hyaluronic acid (HA) is a member of the glycosaminoglycan family of polysaccharides and a major component of the extracellular matrix (ECM). HA is synthesized at the cell surface as a large polysaccharide polymer with very high molecular weight (2 x 10^5 to 10 x 10^7 kDa) and extended length of 2–25 µm [104, 105]. HA is extruded through the plasma membrane onto the cell surface or into the ECM as it is being synthesized. HA is known to be a prominent component of the tumor microenvironment’s ECM, and bladder cancer is characterized by aberrant HA metabolism resulting in increased production in tumor tissue [106–108]. Membrane-bound or free extracellular HA favors tumor progression by inducing tumor cell motility, invasive properties, proliferation, production of growth factors and epithelial-mesenchymal transition [105]. HA is also involved in the regulation, proliferation and differentiation of hematopoietic cells in bone marrow [109].

In addition to the tumor cells, HA can also interact with CD44 receptors expressed by immune cells and other cells of hematopoietic origin. HA modulates expression levels of various cytokines and chemokines in macrophages [110–112]. Additionally, it has been noted that the effect of HA depends on its molecular weight. In general, high molecular weight HA has been shown to be anti-inflammatory and anti-angiogenic. In contrast, fragmented low molecular weight (LMW) HA stimulates expression of pro-inflammatory cytokines, chemokines and growth factors. Furthermore, LMW HA is a potent stimulant of cPLA2 promoting strong release of arachidonate acid, which is a substrate for the inflammation-associated enzymes COX2 and lipoxygenase [113]. In addition, increased levels of HA synthase in cancer tissue correlated with TAM count within tumor mass [114]. Collectively, deregulated HA metabolism in the tumor microenvironment may contribute to the cancer-related inflammation and immune evasion thus promoting tumor growth.

**Conclusion**

Cancer immunotherapy is one of the most effective and promising modalities for cancer treatment. Novel insights into immunology and cancer biology have stimulated research efforts to bring novel immunotherapeutic agents into clinical practice. The last decade has been marked by significant progress in developing, clinical testing and validation of such agents, including immune checkpoint inhibitors, engineered immune cells and novel cancer vaccines. However, the clinical efficacy of cancer immunotherapy is limited due to tumor-induced immune suppression and immune tolerance. Therefore, simultaneous targeting of tumor-induced immune suppression and administration of immunotherapeutic agents has a great potential to boost the anti-tumor immune response and produce a more powerful therapeutic effect than immunotherapy alone. This strategy may be extremely valuable in patients with advanced localized or metastatic bladder cancer which is characterized by high numbers of circulating MDSCs, frequent up-regulation of PD-L1 expression and significant infiltration of tumor tissue with immunosuppressive cell subsets. Recent advances in understanding cellular and molecular mechanisms of immune evasion in bladder cancer provide us with a hope that the therapeutic effects of cancer immunotherapy could be enhanced by pharmacological agents that target specific immunosuppressive components of the tumor microenvironment.

**Author contributions** SK composed the article, wrote review materials related to immune evasion mechanisms and prepared figures. PLC wrote review materials related to immunotherapy of bladder cancer and edited text.

**Funding** This work was supported by the James and Ester King Biomedical Research Program, Florida Health Department, award 8JKO5 and 1923 Fund to Sergei Kusmartsev

**Compliance with ethical standards**

**Conflict of interest** The authors declare that they have no conflict of interest.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
References

1. Okazaki T, Honjo Y (2006) The PD-1–PD-L pathway in immunological tolerance. Trends Immunol 27(4):195–201
2. Egen JG, Kuhns MS, Allison JP (2002) CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 3(7):611–618
3. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH (2011) T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3(95):95ra73
4. Pettenati C, Ingersoll MA (2018) Mechanisms of BCG immunotherapy and its outlook for bladder cancer. Nat Rev Urol 15:615–625
5. Kawai K et al (2013) Bacillus Calmette–Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine. Cancer Sci 104(1):22–27
6. Sylvester RJ (2011) Bacillus Calmette–Guerin treatment of non-muscle invasive bladder cancer. Int J Urol 18:113–120
7. Askeland EJ, Newton MR, O’Donnell MA, Luo Y (2012) Bladder cancer immunotherapy: BCG and beyond. Adv Urol 2012:181987
8. Biot C, Rentsch CA, Gsponer JR, Birkhäuser FD, Jusforgues-Demangel C, Peduto L, Thalmann GN, Albert ML (2012) Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer. Sci Transl Med 4(137):137ra7
9. Svatek RS, Tangen C, Delacrix S, Lowrance W, Lerner SP (2018) Background and update for S1602 “A phase III randomized trial to evaluate the influence of BCG strain differences and patient performance status on the response to intravesical BCG therapy.” J Urol Focus. 4(4):522–524
10. Lamm DL, DeHaven JJ, Shriver J, Sarosdy MF (1991) Prospective randomized comparison of intravesical with percutaneous bacillus Calmette–Guerin versus intravesical bacillus Calmette–Guerin in superficial bladder cancer. J Urol 145(4):738–740
11. Chen L, Han X (2015) Anti-PD1/PD-L1 therapy of human cancers: past, present and future. J Clin Invest 125(9):3384–3391
12. Ansell SM et al (2014) PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med 372(4):311–319
13. Robert C et al (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372(26):2521–2532
14. Garon EB et al (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372(21):2018–2028
15. Brahmer JR et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366(26):2455–2465
16. Powles T, Eder JP, Fine GD, Braiteh SF, Loriot Y, Cruz C et al (2014) MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515:558–562
17. Powles T, Durán I, van der Heijden MS et al (2018) Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomized controlled trial. Lancet 391(10122):748–757
18. Stenehjem DD et al (2018) PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer. Onco Targets Ther. 11:5973–5989
19. Massari F et al (2018) Immune checkpoint inhibitors for metastatic bladder cancer. Cancer Treat Rev 64:11–20
20. Grasselly C et al (2018) The antitumor activity of combinations of cytotoxic chemotherapy and immune checkpoint inhibitors is model-dependent. Front Immunol. 9:2100
21. Xu C et al (2018) Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ 363:k4226
22. Cheng W, Fu D, Zhang Z (2018) Unwrapping the genomic characteristics of urothelial bladder cancer and success with immune checkpoint blockade therapy. Oncogenesis 7:2
23. Pfannstiel C et al (2019) The tumor immune microenvironment drives a prognostic relevance that correlates with bladder cancer subtypes. Cancer Immunol Res 7:923–938
24. Cancer Genome Atlas Research Network (2014) Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507:315–322
25. Nathanson et al (2017) Somatic mutations and neo-epitope homology in melanomas treated with CTLA-4 blockade. Cancer Immunol Res 5:84–91
26. Alegrezza MJ, Conejo-Garcia JR (2017) Targeted therapy and immunosuppression in the tumor microenvironment. Trends Cancer 3(1):19–27
27. Kusmartsev S, Gabrilovich D (2006) Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancer. Cancer Metastasis Rev 25(3):323–331
28. Ostrand-Rosenberg S, Sinha P, Beury DW, Clements VK (2012) Cross-talk between melanoma-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin Cancer Biol 22(4):275–281
29. Hurwitz AA, Watkins SK (2012) Immune suppression in the tumor microenvironment: a role for dendritic cell-mediated tol erization of T cells. Cancer Immunol Immunother 61(2):289–293
30. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E, Chen L (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8(8):793–800
31. Lin H, Wei S, Hurt EM et al (2018) Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. J Clin Invest 128(2):805–815
32. Tang H et al (2018) PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression. J Clin Invest 128(2):580–588
33. Prima V, Kaliberova L, Kaliberov S, Curiel D, Kusmartsev S (2017) COX2-mPGES1-PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells. PNAS 114(5):1117–1122
34. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V (2012) Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 12(4):253–268
35. Senovilla L, Aranda F, Galuzzi L, Kroemer G (2014) Impact of myeloid cells on the efficacy of anticancer chemotherapy. Curr Opin Immunol 30:24–31
36. Bronte V et al (2016) Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. 7:12150
37. Eruslanov E, McCullers M, Daurkin I, Algood C, Dahm P, Rosser CJ, Vieweg E, Gilbert SM, Lu J, Zhu G, Tamada K, Lennon VA, Celis E, Bronte V (2018) Unwrapping the genomic characteristics of urothelial bladder cancer and success with immune checkpoint blockade therapy. Oncogenesis 7:2
38. Eruslanov E, Stoffs T, Kim WJ, Daurkin I, Gilbert SM, Su LM, Vieweg E, Chen L, Lu J, Zhu G, Tamada K, Lennon VA, Celis E, Bronte V (2018) Atezolizumab plus chemotherapy in advanced urothelial bladder cancer. N Engl J Med 378(3):273–283
promotes immunosuppressive phenotype of tumor-infiltrating myeloid cells. Int. J. Immunopharmacol 11(7):848–855
40. Biswas SK, Mantovani A (2010) Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 11(10):889–896
41. Noy R, Pollard JW (2014) Tumor-associated macrophages: from mechanisms to therapy. Immunity 41(1):49–61
42. Saio M, Radoja S, Marino M, Frey AB (2001) Tumor-infiltrating macrophages induce apoptosis in activated CD8(+) T cells by a mechanism requiring cell contact and mediated by both the cell-associated form of TNF and nitric oxide. J Immunol 167(10):5583–5593
43. Kusmartsev S, Gabrilovich D (2005) Critical role of Stat1 signaling in T cell deletion mediated by tumor-associated macrophages. J Immunol 174(8):4880–4891
44. Daurkin I, Erusalov E, Stoffs T, Perrin GQ, Algood C, Gilbert SM, Rosser CJ, Su LM, Vieweg J, Kusmartsev S (2011) Tumor-associated macrophages mediate immune suppression in kidney cancer microenvironment by activating 15-lipoxygenase pathway. Cancer Res 71(20):6400–6409
45. Li Z et al (2016) CD4⁺Foxp3⁺ type 1 regulatory T cells in glioblastoma multiforme suppress T cell responses through multiple pathways and regulated by tumor-associated macrophages. Int J Biochem Cell Biol 81(Pt A):1–9
46. Kryczek I et al (2007) Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res 67(18):8900–8905
47. Mantovani A, Schioppa T, Porta C, Allavena P, Antonio Sica A (2006) Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev 25(3):315–322
48. Erusalov E, Kaliberov S, Daurkin I, Kaliberova L, Buchsbaum D, Vieweg J, Kusmartsev S (2009) Altered expression of 15-hydroxyprostaglandin dehydrogenase in tumor-infiltrated CD11b myeloid cells: a mechanism for immune evasion in cancer. J Immunol 182:7548–7557
49. Kuang DM et al (2009) Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med 206(6):1327–1337
50. Miyake M et al (2017) Regulatory T cells and tumor-associated macrophages in the tumor microenvironment in non-muscle invasive bladder cancer treated with intravesical Bacillus Calmette–Guerin: a long-term follow-up study of a Japanese cohort. Int J Mol Sci 18(10):218
51. Lima L et al (2014) The predominance of M2-polarized macrophages in the stroma of low-hypoxic bladder tumors is associated with BCG immunotherapy failure. Urol Oncol 32(4):449–457
52. Steinman RM, Banchereau J (2007) Developing dendritic cells into medicine. Nature 449:419–426
53. Maldonado RA, Von Andrian UH (2010) How tolerogenic dendritic cells induce regulatory T cells. Adv Immunol 108:111–165
54. Carrascal MA, Severino PF, Guadalupe Cabral M et al (2014) Sialyl Tn-expressing bladder cancer cells induce a tolerogenic phenotype in innate and adaptive immune cells. Mol Oncol 8(3):753–765
55. Waethe N, Moser M (2013) Role of dendritic cells in the regulation of antitumor immunity. OncoImmunology 2(4):e23973
56. Wöllle SI et al (2011) PD-L1 expression on tolerogenic APCs is controlled by STAT-3. Eur J Immunol 41(2):413–424
57. Hori S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299(5609):1057–1061
58. Bettelli E et al (2006) Reciprocal developmental pathways for the generation of pathogenic effector T helpers 17 and regulatory T cells. Nature 441:235–238
59. Park HJ et al (2012) Tumor-infiltrating regulatory T cells delineated by upregulation of PD-1 and inhibitory receptors. Cell Immunol 278(1–2):76–83
60. Whiteside TL (2015) The role of regulatory T cells in cancer immunology. Immunotargets Ther 4:159–171
61. Pichler R et al (2016) Tumor-infiltrating immune cell subpopulations influence the oncolytic outcome after intravesical Bacillus Calmette–Guerin therapy in bladder cancer. Oncotarget 7(26):39916–39930
62. Ooki A et al (2018) YAP1 and COX2 coordinately regulate urethelial cancer stem-like cells. Cancer Res 78(1):168–218
63. Kurtova AV et al (2015) Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance. Nature 517(7533):209–213
64. Yang L, Yamagata N, Yadav R, Brandon S, Courtney R, Morrow J, Shyr Y, Boothby M, Joyce S, Carbone D, Breyer R (2003) Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP₃ receptor. J Clin Invest 111:727–735
65. Harizi H, Juzan M, Pitard V, Moreau J, Gualde N (2002) Cyclooxygenase-2-issued prostaglandin E₂ enhances the production of endogenous IL-10, which down-regulates dendritic cell functions. J Immunol 68:2255–2263
66. Harizi H, Grosset C, Gualde N (2003) Prostaglandin E₂ modulates dendritic cell function via EP2 and EP4 receptor subtypes. J Leukoc Biol 73:756–763
67. Kalinski P (2012) Regulation of immune responses by prostaglandin E₂. J Immunol 188(1):21–28
68. Rodriguez PZ, Hernandes CP, Quisceno D et al (2005) Arginase and its role in myeloid suppressor cells induced by COX-2 in lung carcinoma. J Exp Med 202(7):931–939
69. Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S (2007) Prostaglandin E₂ promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 67(9):4507–4513
70. Baratelli F et al (2005) Prostaglandin E₂ induces FOXP3 gene expression and T regulatory cell function in human CD4 + T cells. J Immunol 175(3):1483–1490
71. Sharma S, Yang SC, Zhu L, Reckamp K, Gardner B, Baratelli F, Huang M, Batra RK, Dubinett SM (2005) Tumor cyclooxygenase-2/prostaglandin E₂-dependent promotion of FOXP3 expression and CD4 + CD25 + T regulatory cell activities in lung cancer. J Immunol 65(12):5211–5220
72. Digiacomo G, Ziche M, Dello Sbarba P, Donnini S, Rovida E (2015) Prostaglandin E₂ transactivates the colony-stimulating factor-1 receptor and synergizes with colony-stimulating factor-1 in the induction of macrophage migration via the mitogen-activated protein kinase ERK1/2. FASEB J. 29(6):2545–2554
73. Fruci D, Lo Monaco E, Cifaldi L, Locatelli F, Tremante E, Benevolo M, Giacomini P (2013) T and NK cells: two sides of tumor immunity. J Transl Med 11:30–35
74. Stolina M, Sharma S, Lin Y, Dohadwala M, Gardner B, Luo J, Zhu L, Kronenberg M, Miller PW, Portanova J, Lee JC, Dubinett SM (2000) Specific inhibition of cyclooxygenase-2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol. 164(1):361–370
75. Haas AR et al (2016) Cyclooxygenase-2 inhibition augments the efficacy of a cancer vaccine. Clin Cancer Res 12(1):214–222
76. Euslanov E, Daurkin I, Ortiz J, Vieweg J, Kusmartsev S (2010) Pivotal Advance: tumor-mediated induction of myeloid-derived suppressor cells and M2-polarized macrophages by altering intracellular PGE₂ catabolism in myeloid cells. J Leukoc Biol 88(S):839–848
77. Rodriguez-Ubreva J et al (2017) Prostaglandin E2 Leads to the acquisition of DNMT3A-dependent tolerogenic functions in human myeloid-derived suppressor cells. Cell Rep 21(1):154–167
78. Daurkin I, Eruslanov E, Vieweg J, Kusmartsev S (2010) Generation of antigen-presenting cells from tumor-infiltrated CD11b myeloid cells with DNA demethylating agent 5-aza-2'-deoxycytidine. Cancer Immunol Immunother 59(5):697–706
79. Sombrook CC et al (2002) Prostanoids play a major role in the primary tumor-mediated induction of dendritic cell differentiation. J Immunol 168(9):4333–4343
80. Heusinkveld M et al (2011) M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells. J Immunol 187(3):1157–1165
81. Mao Y, Sarhan D, Steven A, Seliger B, Kiessling R, Lundqvist (2010) Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol Med 16:133–144
82. Chomarat P, Banchereau J, Davoust J, Palucka AK (2000) IL-6 switches the differentiation of monocytes from dendritic cells to natural killer cell activity. Clin Cancer Res 20(15):4096–4106
83. Hiratsuka S, Watanabe A, Aburatani H, Maru Y (2007) Tumour-mediated upregulation of chemoattracrants and recruitment of myeloid cells predetermines lung metastases. Nat Cell Biol 8:1369–1375
84. Lazenec G, Richmond A (2010) Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol Med 16:133–144
85. Qian BZ et al (2011) CCL2 recruits inflammatory monocytes to the primary tumor and facilitates lymph node dissemination and metastasis of breast cancer. Cancer Immunol Immunother 59(6):707–715
86. Qian BZ (2017) Inflammation fires up cancer metastasis. Semin Cancer Biol 47:174–181
87. Khaldoyanidi S et al (2014) Hyaluronan in the healthy and malignant hematopoietic microenvironment. Adv Cancer Res. 123:149–189
88. Kitamura T et al (2015) CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages. J Exp Med 212(7):1043–1059
89. Chen C et al (2018) LNMAT1 promotes lymphatic metastasis of bladder cancer via CCL2-dependent macrophage recruitment. Nat Commun 9(1):3826
90. Sironen RK et al (2011) Hyaluronan in human malignancies. Exp Cell Res 317(4):383–391
91. Lyon PA et al (2015) CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages. J Exp Med 212(7):1043–1059
92. Qian BZ (2017) Inflammation fires up cancer metastasis. Semin Cancer Biol 47:174–181
93. Chen C et al (2018) LNMAT1 promotes lymphatic metastasis of bladder cancer via CCL2-dependent macrophage recruitment. Nat Commun 9(1):3826
94. Gonzalez J, Qui Y, Lora J, Al-Garawi A, Villeval J, Boyce J, Martinez A, Marquez G, Goya I, Hamid Q et al (2007) Coordination of mast cells and T cells in allergic mucosal inflammation: critical role of the CC chemokine ligand 1: CCR8 axis. J Immunol 179:1740–1750
95. Heymann F, Hammerich L, Storch D, Bartneck M, Huss S, Rüüssel V, Gassler N, Lira S, Luedde T, Trautwein C, Tacke F (2012) Hepatic macrophage migration and differentiation critical for liver fibrosis is mediated by the chemokine receptor CCR8. Hepatology 55(3):989–909
96. Hoelzinger D, Vieweg J, Goya I, Marquez G, Goya I, Hamid Q et al (2007) Coordination of mast cells and T cells in allergic mucosal inflammation: critical role of the CC chemokine ligand 1: CCR8 axis. J Immunol 179:1740–1750
97. Heymann F, Hammerich L, Storch D, Bartneck M, Huss S, Rüssel V, Gassler N, Lira S, Luedde T, Trautwein C, Tacke F (2012) Hepatic macrophage migration and differentiation critical for liver fibrosis is mediated by the chemokine receptor CCR8. Hepatology 55(3):989–909
98. Hoelzinger D, Vieweg J, Goya I, Marquez G, Goya I, Hamid Q et al (2007) Coordination of mast cells and T cells in allergic mucosal inflammation: critical role of the CC chemokine ligand 1: CCR8 axis. J Immunol 179:1740–1750
99. Rüssel V, Gassler N, Lira S, Luedde T, Trautwein C, Tacke F (2012) Hepatic macrophage migration and differentiation critical for liver fibrosis is mediated by the chemokine receptor CCR8. Hepatology 55(3):989–909
100. Hoelzinger D, Vieweg J, Goya I, Marquez G, Goya I, Hamid Q et al (2007) Coordination of mast cells and T cells in allergic mucosal inflammation: critical role of the CC chemokine ligand 1: CCR8 axis. J Immunol 179:1740–1750
101. Khaldoyanidi S et al (2014) Hyaluronan in the healthy and malignant hematopoietic microenvironment. Adv Cancer Res. 123:149–189
102. Khaldoyanidi S, Moll J, Karakhanova S, Herrlich P, Ponta H (1999) Hyaluronate-enhanced hematopoiesis: two different receptors trigger the release of interleukin-1beta and interleukin-6 from bone marrow macrophages. Blood 94(3):940–949
103. Jiang D et al (2005) Regulation of lung injury and repair by Toll-like receptors and hyaluronan. J Immunol 184:6833–6842
104. Girish KS, Kemparaju K (2007) The magic glue hyaluronan and its eraser hyaluronidase: a biological overview. Life Sci 80:1921–1943
105. Toole BP (2004) Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 4(7):528–539
106. Simpson MA, Lokeshrav VB (2008) Hyaluronan and hyaluronidase in genitourinary tumors. Front Biosci 13:5664–5680
107. Sironen RK et al (2011) Hyaluronan in human malignancies. Exp Cell Res 317(4):383–391
108. Kramer MW et al (2010) HYAL-1 hyaluronidase: a potential prognostic indicator for progression to muscle invasion and recurrence in bladder cancer. Eur Urol 1:86–93
109. Khaldoon A et al (2014) Hyaluronan in the healthy and malignant hematopoietic microenvironment. Adv Cancer Res. 123:149–189
110. Khaldoon A et al (2014) Hyaluronan in the healthy and malignant hematopoietic microenvironment. Adv Cancer Res. 123:149–189
111. Sokolowska M, Chen LY, Eberlein M et al (2014) Low molecular weight hyaluronan and its eraser hyaluronidase as a negative prognostic indicator for progression to muscle invasion and recurrence in bladder cancer. Histopathology 66(6):873–883
112. Rayahin JE et al (2015) High and low molecular weight hyaluronic acid differentially influence macrophage activation. ACS Biomater Sci Eng 1(7):481–493
113. Sokolowska M, Chen LY, Eberlein M et al (2014) Low molecular weight hyaluronan activates cytosolic phospholipase A2 and eicosanoid production in monocytes and macrophages. J Biol Chem 289(7):4470–4488
114. Tainen S et al (2015) High numbers of macrophages especially M2-like (CD163-positive) correlate with hyaluronan accumulation and poor outcome in breast cancer. Histopathology 66(6):873–883

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.